Time to recognise gout as a chronic disease

Keen, Helen; Robinson, Philip C; Dalbeth, Nicola; Hill, Catherine J.

doi:10.5694/mja2.50512

Cited by 4 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite gout being reversible and preventable with urate‐lowering therapy (ULT), it is often poorly treated, 2 associated with poor medication adherence 9,10 and under‐reported 3,11 . Gout is treatable by reducing the serum urate to below the saturation point for monosodium urate 12,13 .…”

Section: Introductionmentioning

confidence: 99%

“…7,8 Despite gout being reversible and preventable with urate-lowering therapy (ULT), it is often poorly treated, 2 associated with poor medication adherence 9,10 and under-reported. 3,11 Gout is treatable by reducing the serum urate to below the saturation point for monosodium urate. 12,13 This promotes crystal dissolution and prevents new crystal formation, leading to fewer attacks of inflammatory arthritis and prevention of joint destruction and renal disease.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The disproportionately large contribution of the Māori and Pacific Islander community to the healthcare burden of gout in Western Sydney

Wong

Mitchell

et al. 2022

Internal Medicine Journal

View full text Add to dashboard Cite

BackgroundGout is a common chronic inflammatory disorder due to monosodium urate deposition, which results in severe inflammatory arthritis. It is particularly common in those of Māori or Pacific Islander heritage. There is a significant number of this at‐risk ethnic group in western Sydney.AimsTo determine the healthcare burden of gout in Western Sydney.MethodsWe characterised patients managed in the emergency departments (EDs) of the four Western Sydney Local Health District (WSLHD) hospitals and those admitted for gout as the primary or secondary diagnosis from 1 January 2017 to 31 December 2018.ResultsThere were 472 patients managed in ED on 552 occasions at a direct cost to the LHD of A$367 835. Those of Māori or Pacific Islander ethnicity comprised 25.2% (n = 119/472), while half (n = 39/80) of those managed in ED for gout on two or more occasions were of Māori or Pacific Islander ethnicity. Overall, 310 patients were admitted with gout as the principal diagnosis on 413 occasions at a cost of A$1.73 million. Seventy‐five (24.2%) of the 310 patients were of Māori or Pacific Islander heritage. A total of 584 WSLHD inpatients had gout as a secondary diagnosis. This was associated with 714 admissions.ConclusionsThe disproportionately large healthcare burden of gout in Western Sydney from the relatively small Māori and Pacific Islander population needs attention. Urgent culturally appropriate interventions to address gout are required to address this inequality.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The disproportionately large contribution of the Māori and Pacific Islander community to the healthcare burden of gout in Western Sydney

Wong

Mitchell

et al. 2022

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

“…Physicians tend to believe gout has a moderate impact on emotions and life, and only a few routinely offer lifestyle advice to patients with gout [ 45 ]. In Australia, the prevalence of gout varies from 0.8% (self-reported) to 6.8% (self-reported doctor diagnosed gout), showing a poor understanding of the condition among patients [ 46 , 47 ]. Moreover, there are studies reporting discordance between patients and physicians on a presence of a gout flare, with a rate as high as 30% [ 48 ].…”

Section: Discussionmentioning

confidence: 99%

Medical Students’ Perspective and Knowledge of Asymptomatic Hyperuricemia and Gout Management: A Cross-Sectional Study

et al. 2021

View full text Add to dashboard Cite

The prevalence and incidence of gout doubled from 1990 to 2017. Therefore, we can expect that a number of doctors have come across a patient with gout in their daily practice. Hence, we wanted to investigate how familiar our medical students, as future medical professionals, are with gout. This cross-sectional survey included Medical Studies students from the two largest universities in Croatia: the University of Split School of Medicine, and the University of Zagreb School of Medicine, and included a total of 221 fifth or sixth year medical students. Most students gave correct answers to questions about treatment approach and non-pharmacological interventions in asymptomatic hyperuricemia (>80%). Less than 3% of all students agreed they knew enough about care for patients with asymptomatic hyperuricemia, whereas almost 15% thought they were well familiar with care for gout patients. Less than 8% of students considered their school education adequate on both topics, and less than 2% were aware of the existence of EULAR guidelines. Physicians lacking in the latest knowledge on the pathophysiology of gout, the influence of lifestyle, and genetic factors limits their ability to properly manage gout. With increasing prevalence, gout should be more represented in medical students’ education.

show abstract

Microneedle transdermal drug delivery as a candidate for the treatment of gouty arthritis: Material structure, design strategies and prospects

Yi,

Yu,

Wang

et al. 2024

Acta Biomaterialia

View full text Add to dashboard Cite

Time to recognise gout as a chronic disease

Cited by 4 publications

References 4 publications

The disproportionately large contribution of the Māori and Pacific Islander community to the healthcare burden of gout in Western Sydney

The disproportionately large contribution of the Māori and Pacific Islander community to the healthcare burden of gout in Western Sydney

Medical Students’ Perspective and Knowledge of Asymptomatic Hyperuricemia and Gout Management: A Cross-Sectional Study

Microneedle transdermal drug delivery as a candidate for the treatment of gouty arthritis: Material structure, design strategies and prospects

Contact Info

Product

Resources

About